Document is current
Any future updates will be listed below
-
Authors
Rindi, Guido https://orcid.org/0000-0003-2996-4404
Mete, Ozgur https://orcid.org/0000-0003-0469-2801
Uccella, Silvia https://orcid.org/0000-0002-5714-7295
Basturk, Olca https://orcid.org/0000-0003-2747-1366
La Rosa, Stefano https://orcid.org/0000-0003-1941-2403
Brosens, Lodewijk A. A. https://orcid.org/0000-0003-1341-8994
Ezzat, Shereen
de Herder, Wouter W. https://orcid.org/0000-0003-1463-5165
Klimstra, David S. https://orcid.org/0000-0001-8814-1702
Papotti, Mauro https://orcid.org/0000-0002-2713-1700
Asa, Sylvia L. https://orcid.org/0000-0001-8418-5054
- License Information
-
More Information
Article History
Accepted: 28 January 2022
First Online: 16 March 2022
Declarations
:
: Not applicable.
: All authors consent to publication.
: Dr. Guido Rindi has had speaker engagements for the Advanced Accelerator Applications (AAA), a Novartis company. Dr. Shereen Ezzat has had speaker engagements for Novartis and Ipsen. Dr. David Klimstra is the Chief Medical officer (employee and equity holder) of Paige.AI. Dr. Ozgur Mete is the Editor-in-Chief of <i>Endocrine Pathology</i>. An independent senior editor handled this article and peer reviewed as per the journal standards. The remaining authors declare that they have no competing interest.
